B2i Digital backs ROTH healthcare conference in New York

B2i Digital is serving as marketing partner for ROTH Capital Partners’ 5th Annual ROTH Healthcare Opportunities Conference on Sept. 29 at The Metropolitan Club in New York City. The invitation-only event is built around 25-minute investor meetings and panels featuring public healthcare companies across biotech, diagnostics and medtech.

Why it matters: - The conference gives institutional investors direct access to C-level executives from public healthcare companies in one day of scheduled meetings. - The format is built for deal flow, capital raising and corporate access across biotech, life science tools and diagnostics, and medtech. - B2i Digital is using the event as a Featured Conference, extending its role in connecting capital markets audiences with company management teams.

What happened: - B2i Digital is serving as marketing partner for the 5th Annual ROTH Healthcare Opportunities Conference. - ROTH Capital Partners is hosting the event on Tuesday, Sept. 29, 2026, at The Metropolitan Club in New York City. - The conference runs from 8:00 AM to 4:30 PM. - The event is invitation-only, and registration requires approval by ROTH. - Event details and participating company profiles are available here. - Registration requests go through the conference registration page.

The details: - ROTH built the program around 25-minute 1-on-1 and small group meetings. - The meetings connect institutional clients with public healthcare company executives. - Confirmed participants as of Aug. 21, 2026 include 908 Devices, Akari Therapeutics, Alpha Teknova, Annovis Bio, Arcturus Therapeutics, BioAge Labs, Biodesix, CapsoVision, CervoMed, Cingulate Therapeutics, Clene, Eos SENOLYTIX, Equillium, Gain Therapeutics, MAXONA Pharmaceuticals, MediciNova, Medicus Pharma, Moleculin Biotech, NeuroSense Therapeutics, Newron Pharmaceuticals, OS Therapies, Ovid Therapeutics, Polaryx Therapeutics, PolyPid, ProMIS Neurosciences, Rapid Micro Biosystems, Revelation Biosciences, Serina Therapeutics, Stereotaxis, Trulieve Cannabis and vTv Therapeutics. - Panel sessions include Frontiers in Neuroscience with Annovis Bio, CervoMed, Gain Therapeutics, MediciNova and ProMIS Neurosciences. - Dr. Frank Lichtenberg, professor emeritus of healthcare management at Columbia University, is scheduled to speak on The Economics of Drug Value: What It Means for Pricing and Coverage. - The Biotech Reset panel will address regulatory uncertainty, capital constraints and the search for value, with Kendall Square Policy Strategies, PolyPid and Newron Pharmaceuticals. - The Rise of MRD Monitoring in Solid Tumors, and Where it Goes Next will feature Biodesix, DeciBio and Memorial Sloan Kettering Cancer Center. - B2i Digital said it supports the conference through digital marketing, its media network, social media and company profiles. - David Shapiro, B2i Digital chief executive officer, said the fall conference season opener will again deliver an “exceptional experience” for investors and companies.

Between the lines: - The conference points to continued investor interest in healthcare names even as the sector faces regulatory and financing pressure. - The panel lineup suggests the market is focused on neuroscience, drug pricing, biomarker monitoring and business model reset stories. - The invitation-only structure reinforces the conference’s role as a curated meeting venue rather than a broad trade show.

What's next: - More companies may be added before the event, since the participant list is subject to change. - Approved investors and participating companies will meet in New York on Sept. 29 for one-on-one and small-group sessions. - ROTH and B2i Digital will continue promoting the conference through their digital and media channels.

The bottom line: - ROTH’s New York healthcare conference is set up to compress investor access, executive meetings and sector debate into a single day.